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a  b  s  t  r  a  c  t
Background  and  purpose:  Thromboembolic  risk  has  been  examined  by  semi-invasive  transesophageal
echocardiography.  We  assessed  the  risk  of  thrombogenesis  in  patients  with  persistent  atrial  ﬁbrillation
(AF)  noninvasively  by  using  transthoracic  tissue  Doppler  echocardiography  (TDE)  in  relation  to  a  low
CHADS2  score.
Methods: Eighty  patients  with  persistent  AF  underwent  both  transthoracic  and  transesophageal  echocar-
diography.  Peak  left atrial appendage  (LAA),  wall  motion  velocity  (WV)  during  LAA contraction  was
measured  by  transthoracic  and  transesophageal  TDE.  LAA  ﬂow  velocity  was  also  determined  by  trans-
esophageal  echocardiography.
Results: Transthoracic  LAAWV  could  be measured  in 78  of the  80 patients,  and  the  values  were  closely  cor-
related with  transesophageal  TDE  values  (r = 0.98)  and  with  transesophageal  LAA  ﬂow  velocity  (r =  0.82).
Transthoracic  LAAWV  was  signiﬁcantly  lower  with  increasing  spontaneous  echo  contrast  (SEC) severity
(severe  SEC,  mild  SEC,  no SEC:  5.7  ± 2.4, 10.2  ± 3.3,  and  14.5 ± 5.5 cm/s,  respectively).  Severe  SEC  was
noted  in  31  of  61  patients  with  a  CHADS2  score  ≤2,  in  19  of  46  patients  with  a CHADS2  score  ≤1  and  in 6
of  21 patients  with  a CHADS2  score  = 0.  For  diagnosing  severe  SEC,  a  transthoracic  LAAWV  <10  cm/s  had
a sensitivity  of  81%  and  speciﬁcity  of 92%  in  the patients  with  a  CHADS2  score  ≤2, a sensitivity  of  74%  and
speciﬁcity  of  91%  in the  patients  with  a CHADS2  score  ≤1  and  a sensitivity  of  44%  and  speciﬁcity  of 83%
in the  patients  with  a CHADS2  score  = 0.
Conclusions:  A  transthoracic  LAAWV  <10 cm/s  in  persistent  AF  patients  with  a low  CHADS2  score  may  be a
very  speciﬁc  diagnostic  tool  for  evaluating  severe  SEC,  one  of the  high  risk  factors  for thromboembolism.
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Cerebral infarction induced by cardiogenic embolism is
bserved in 13–34% of stroke patients [1].  Cardiogenic cerebral
mbolism is most frequently caused by atrial ﬁbrillation (AF). The
educed left atrial function in patients with AF may  result in throm-
us formation in the left atrial appendage (LAA). The functional
arameters of the LAA such as ﬂow velocity, fractional change dur-
ng atrial contraction, and spontaneous echo contrast (SEC) have
een previously assessed by transesophageal echocardiography.
n LAA ﬂow velocity of <20 cm/s and prominent SEC are high-risk
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factors for cerebral embolism [2,3]. LAA wall motion velocity
(LAAWV), which is an indicator of LAA function and thromboge-
nesis risk, has been measured by transesophageal tissue Doppler
echocardiography (TDE) [4–9]. However, since this is a semi-
invasive method, its application as a screening tool is limited.
Therefore, an alternative noninvasive method for assessing LAA
function is required.
Recent developments in transthoracic echocardiography and
new technology have facilitated the evaluation of the size, ﬂow
velocities, and emptying fraction of the LAA [10–12].  Moreover,
LAA function in patients with sinus rhythm and AF has been deter-
mined by transthoracic TDE. Transthoracic TDE can predict the risk
of thromboembolism in patients with a history of stroke or tran-
sient ischemic attack [13–15].  On the other hand, the CHADS2 score
is a widely used clinical index for evaluating the risk of thromboem-
bolism and initiating anticoagulant therapy in patients with AF
[16]. Recently, CHA(2)DS(2)-VASc scores have been also proposed
vier Ltd. All rights reserved.
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Table  1
Patient characteristics.
Variables Atrial ﬁbrillation patients
Number 78
Men 56
Age  (years) 69 ± 9
HT  24
DM  14
Congestive heart failure 26
Warfarin 25
CHADS2 score ≥ 3 17
CHADS2 score = 2 15
CHADS2 score = 1 25
CHADS2 score = 0 21
LAAV (cm/s) 31 ± 21
LAAA (mm2) 507 ± 201
LAAFC (%) 26 ± 18
LAAWV by TEE (cm/s) 8.0 ± 4.7
LAAWV by TTE (cm/s) 8.3 ± 4.8
LAD  (mm)  45 ± 8
HT, hypertension; DM,  diabetes mellitus; Warfarin, administration before this
study; LAAV, left atrial appendage (LAA) ﬂow velocity during atrial contraction;








































bacic echocardiography; LAAFC, LAA fractional change during atrial contraction;
AAWV, LAA wall motion velocity during LAA contraction; LAD, left atrial dimension.
or evaluating the risk of ischemic stroke/cardiovascular events in
apanese patients with paroxysmal AF or for predicting clinical out-
omes in patients with atrial ﬁbrillation after catheter ablation in
sian patients [17,18].  A high CHADS2 score, especially including
troke with a value of 2, indicates the need for anticoagulation
herapy in patients with persistent AF. The score may  be useful
or secondary prevention of stroke in patients with persistent AF.
owever, these scores are not always consistent with the left atrial
LA) function. Reduced LA function may  result in blood stasis in the
A and may  cause cardiogenic cerebral embolism. The reduced LA
unction may  cause SEC in the LA. The severity of SEC is strongly
ssociated with LAA thrombus and embolic events [19]. Therefore,
he ability to predict the severity of SEC in the LA would be clin-
cally useful because we currently anticoagulate all patients with
evere SEC. It is very important to noninvasively evaluate severe
EC in patients without a stroke history and with a low CHADS2
core. In this study, we examined the diagnostic role of transtho-
acic LAAWV in relation to the CHADS2 score for evaluating the risk
f thrombosis or blood stasis in patients with persistent AF.
aterials and methods
articipants
The study population comprised 80 consecutive patients with
ersistent nonvalvular AF who underwent both transthoracic and
ransesophageal echocardiography in our laboratory from October
008 to January 2010. Transesophageal echocardiography was
rdered by cardiologists or neurologists for examining the risk of
hromboembolism in the patients with AF. The data were retro-
pectively analyzed. Persistent AF was deﬁned as AF lasting more
han 1 week according to the past electrocardiography or clinical
ymptoms. Their mean age was 69 ± 9 years. Patients predisposed
o aortic arch and carotid sources were not included in the study.
he characteristics of the 78 patients in whom LAAWV could be
easured using transthoracic TDE are shown in Table 1. Among
he 78 patients, 61 had a CHADS2 score ≤2, and 17 had a CHADS2
core ≥3. There were 46 patients with a CHADS2 score ≤1 and 21
atients with CHADS2 score = 0. Twenty-ﬁve patients had received
nticoagulation therapy before participation in this study. There
ere 9 cases of new cerebral embolism that were diagnosed on the
asis of the clinical signs and ﬁndings from magnetic resonanceiology 60 (2012) 310–315 311
imaging, computed X-ray tomography, and cerebral angiography,
or a combination of these methods. If strong anticoagulation ther-
apy for the acute phase of cerebral infarction is started too early,
it may  cause bleeding in the infarction area. Therefore, the neu-
rologist in our hospital did not administer warfarin during the
super-acute phase of cerebral infarction. Furthermore, in persis-
tent AF, decisions regarding anticoagulation therapy depend on
the transesophageal echocardiographic ﬁndings; therefore, a small
number of patients underwent anticoagulation therapy before this
study.
Written informed consent was obtained from all participants.
Echocardiographic apparatus
Both transthoracic and transesophageal echocardiographic
examinations were conducted with an ultrasound system (Vivid
7; General Electric Healthcare, Milwaukee, WI,  USA). The mea-
surement speciﬁcations for transthoracic TDE were as follows:
frame rate, 141 frames/s; frequency, 2.6 MHz; and sampling vol-
ume  width, 3.3 mm.  As described previously, the corresponding
measurements for transesophageal TDE were as follows: frame
rate, 78 frames/s; frequency, 3.9 MHz; and sampling volume width,
3.2 mm [20].
Transesophageal echocardiography
The peak LAA ﬂow velocity (LAAV) during LAA contraction
and the change in the LAA fractional area during atrial contrac-
tion (LAAFC) were recorded using conventional transesophageal
echocardiography in the long-axis view. We  examined the pres-
ence of SEC in the LA body and LAA. In the present study, if SEC
was visible only when the echo gain was increased by 4 dB from
the normal gain setting, we  deﬁned it as mildly positive. If SEC was
visible at the normal gain setting, we deﬁned it as severe. The nor-
mal  gain setting was deﬁned as no excessive noise echo in the other
cardiac cavity [20]. When the severity of SEC differed between the
LA body and LAA, the stronger grade was recorded as the sever-
ity. The presence of thrombi and the severity of SEC were assessed
by 3 independent investigators using transesophageal echocardio-
graphy. Furthermore, the LAAWV at the tip of the LAA during LAA
contraction was determined using pulsed transesophageal TDE, and
the maximum positive peak wave velocity within each RR interval
was averaged over 10 cardiac cycles. At that time, the mitral ring
motion artifacts were carefully neglected.
Angle correction was not performed because the Doppler beam
was almost parallel to the motion of the longitudinally contracting
appendage (Fig. 1).
Transthoracic echocardiography
LAAWV was measured using transthoracic TDE within 1 h of
the transesophageal echocardiography examination. The triangle-
shaped LAA on the left side of the aortic root in the parasternal
short-axis view was  identiﬁed. The sample volume was  placed very
close to the tip of the LAA, and the LAAWV was measured using
pulsed transthoracic TDE (Fig. 1).
LAAWV was calculated as the average of the maximum negative
peak wave velocity within each RR interval over 10 cardiac cycles
excluding the mitral ring motion signals (Fig. 2). The Doppler beam
angle was corrected by observing the direction of the longitudinally
contracting appendage (Fig. 1). The LA dimension was convention-
ally measured using M-mode transthoracic echocardiography.
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Fig. 1. Measurement of LAAWV during the LAA contraction phase using pulsed tissue Doppler echocardiography with transesophageal (left panel) and transthoracic (right
panel)  echocardiography in patients with atrial ﬁbrillation. The sample volume (dotted arrows) for LAAWV measurement was placed at the tip of the LAA. The average
maximum positive peak wave within each RR interval during LAA contraction was designated as LAAWV. AO, aorta; LA, left atrium; LAA, left atrial appendage; LAAWV, left












vig. 2. LAAWV during the LAA contraction phase was  measured using pulsed tiss
anel)  were measured using transthoracic echocardiography in patients with atrial 
re  sometimes mistaken for LAAWV readings. Electrocardiographic monitoring is n
trium; LAA, left atrial appendage; LAAWV, left atrial appendage wall velocity; LV, tatistical analysis
Simple linear regression analysis was used to determine cor-
elations between different parameters. The differences in the
able 2
haracteristics of atrial ﬁbrillation patients with or without SEC.
Variables Severe SEC M
Number 48 
Men  33 
Age  (years) 69 ± 9 
HT  17 
DM 9  
Warfarin 21 
Thrombus in LAA 13 
Cerebral embolism 9 
CHADS2 score 2.1 ± 1.4 
LAAV (cm/s) 19 ± 13 
LAAA (mm2) 533 ± 224 4
LAAFC  (%) 16 ± 12 
LAAWV by TEE (cm/s) 5.3 ± 1.8 1
LAAWV by TTE (cm/s) 5.7 ± 2.4 1
LVEF (%) 61 ± 12 
LAD  (mm) 48 ± 7 
EC, spontaneous echo contrast; NS, not statistically signiﬁcant; p-values indicate differen
T,  hypertension; DM,  diabetes mellitus; Warfarin, administration before this study; LAAV
AA  area; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography;
elocity during LAA contraction; LAD, left atrial dimension.
* Statistically signiﬁcant.ppler echocardiography (left panel), and the mitral annular motion signals (right
tion. When the LAAWV (solid lines) is low, mitral ring motion signals (dotted lines)
ry to differentiate LAAWV from mitral ring signals (dotted lines). AO, aorta; LA, left
ntricle; RA, right atrium; ROI, region of interest; RV, right ventricle.values between the two groups were examined using unpaired t-
tests, and the differences in the values among the three groups
were examined using analysis of variance (ANOVA) with a Bonfer-
roni correction. The LAAWV cutoff value for diagnosing cerebral
ild SEC No SEC p value
17 13 –
13 10 NS






0.8 ± 0.7 0.5 ± 0.7 <0.001*
38 ± 16 60 ± 19 <0.001*
89 ± 164 441 ± 150 NS
36 ± 19 43 ± 12 <0.001*
0.6 ± 3.5 14.1 ± 5.3 <0.001*
0.2 ± 3.3 14.5 ± 5.5 <0.001*
66 ± 6 61 ± 14 NS
42 ± 8 40 ± 7 <0.001*
ces among 3 groups according to analysis of variance with a Bonferroni adjustment;
, left atrial appendage (LAA) ﬂow velocity during atrial contraction; LAAA, maximal
 LAAFC, LAA fractional change during atrial contraction; LAAWV, LAA wall motion
N. Yoshida et al. / Journal of Card
Fig. 3. Regression analysis of LAAWV measured by transesophageal and transtho-

























das  applied for transthoracic echocardiography. LAAWV, left atrial appendage wall
elocity; TEE, transesophageal echocardiography; TTE, transthoracic echocardiog-
aphy.
mbolism and/or LAA thrombus and for diagnosing severe SEC
as approximately half (10 cm/s) the normal value (22 ± 3 cm/s)
entioned in a study involving healthy individuals [21]. The sen-
itivity, speciﬁcity, and predictive values for diagnosing cerebral
mbolism, LAA thrombus, and severe SEC were determined using
AAWV and CHADS2 scores (Table 3). We  grouped the patients with
mbolism and/or LA thrombosis together as having LA thrombus.
he Statistical Package for the Social Sciences (SPSS version 11.0J;
PSS Japan Inc., Tokyo, Japan) was used for all statistical analy-
es except diagnostic accuracy. Statistical signiﬁcance was set at
 < 0.05.
Interobserver variability in the LAAWV measurements was
alculated as the difference between two measurements of the
ame subject performed by two different observers divided by the
ean value. Intraobserver variability was calculated as the differ-
nce between two measurements of the same subject by a single
bserver, divided by the mean value.
The study protocol was approved by our institutional review
oard.
esultsalidation of transthoracic LAAWV measurement
LAAWV was successfully measured using transthoracic TDE
n 78 of the 80 patients (98%). The transthoracic LAAWV
ig. 4. LAAWV plotted against LAA ﬂow velocity during LAA contraction (LAAV) in patie
uring  atrial contraction (LAAFC) (right panel). LAA, left atrial appendage; LAAWV, left atiology 60 (2012) 310–315 313
patterns were reproducible and similar to those of transesophageal
LAAWV in these AF patients (Fig. 1). The LAAWV values deter-
mined by transthoracic TDE ranged from 2 to 26 cm/s in patients
with persistent nonvalvular AF. The LAAWV values determined
by transthoracic and transesophageal TDE did not differ signiﬁ-
cantly (9.0 ± 5.9 vs. 8.7 ± 5.9 cm/s, respectively) and were strongly
correlated (r = 0.98) (Fig. 3). LAAWV was  signiﬁcantly correlated
with transesophageal LAAV (r = 0.82, p < 0.001) and LAAFC (r = 0.56,
p < 0.001) (Fig. 4).
The intra- and interobserver variabilities in LAAWV measure-
ment by transthoracic TDE were 5.6% and 6.8%, respectively.
LAAWV measured by transthoracic TDE in relation to thrombosis
and blood stasis
Transthoracic LAAWV values were signiﬁcantly lower in
patients with cerebral embolism or LAA thrombus than in
patients without these conditions (5.0 ± 2.2 vs. 9.3 ± 4.9 cm/s,
p < 0.001). Transthoracic LAAWV values were signiﬁcantly lower
with increasing SEC severity (severe SEC, mild SEC, with-
out SEC: 5.7 ± 2.4, 10.2 ± 3.3, and 14.5 ± 5.5 cm/s, respectively)
(Table 2).
Thrombosis risk evaluation using transthoracic LAAWV and
CHADS2 score
A CHADS2 score ≥3 had high sensitivity and speciﬁcity (88%
and 97%, respectively) for diagnosing cerebral embolism and/or
LAA thrombus, but low speciﬁcity (49%) for diagnosing severe
SEC.
In the 78 patients, a transthoracic LAAWV <10 cm/s had a sen-
sitivity, speciﬁcity, and positive and negative predictive values of
86%, 88%, 94%, and 77% for diagnosing severe SEC. Among the 61
persistent AF patients with a CHADS2 score ≤2, embolism and/or
LAA thrombus were observed in 2 and severe SEC was  noted in
31. Severe SEC was  noted in 13 of the 46 persistent AF patients
with a CHADS2 score ≤1, and in 6 of the 21 persistent AF patients
with a CHADS2 score 0. In the 61 patients with a CHADS2 score ≤2,
a transthoracic LAAWV <10 cm/s had a sensitivity, speciﬁcity, and
positive and negative predictive values of 81%, 92%, 94%, and 77%
for diagnosing severe SEC, respectively. In the 46 patients with a
CHADS2 score ≤1, a transthoracic LAAWV <10 cm/s had a sensitiv-
ity, speciﬁcity, and positive and negative predictive values of 74%,
91%, 89%, and 77% for diagnosing severe SEC, respectively (Table 3).
In the 21 persistent AF patients with a CHADS2 score 0, a transtho-
racic LAAWV was 6.8 ± 4.1 cm/s in 6 patients with severe SEC and
nts with atrial ﬁbrillation (left panel). LAAWV plotted against LAA fractional area
rial appendage wall velocity.
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Table 3
Accuracy of diagnosis of severe SEC patients using transthoracic LAAWV <10 cm/s.
Variables Sensitivity (%) Speciﬁcity (%) Positive predictive
value (%)
Diagnosing severe SEC 86 88 94
Diagnosing severe SEC in patients with a CHADS2 score ≤ 2 81 92 94
















































iDiagnosing severe SEC in patients with a CHADS2 score = 0 44
EC, spontaneous echo contrast; LAAWV, left atrial appendage wall motion velocity
as 13.0 ± 6.0 cm/s in 15 patients without severe SEC (p = 0.015).
n the 21 persistent AF patients with a CHADS2 score 0, a transtho-
acic LAAWV <10 cm/s had a sensitivity, speciﬁcity, and positive and
egative predictive values of 44%, 83%, 66%, and 67% for diagnosing
evere SEC.
iscussion
alidation of transthoracic LAAWV for assessing LAA function
Previous studies using transthoracic pulsed Doppler echocar-
iography successfully measured Doppler ﬂow velocities in 62–88%
f patients [10,11].  Recently, transthoracic TDE, a noninvasive
ethod, was demonstrated to be useful for analyzing LAA function
n patients with AF [13–15,20].  In the present study, we suc-
essfully determined LAAWV in 98% of the patients with AF by
sing transthoracic TDE. In addition, the strong correlation between
ransthoracic and transesophageal LAAWV measurements in the
resent study may  validate the use of transthoracic TDE. Both intra-
nd inter-observer variabilities in transthoracic LAAWV measure-
ents were low. These ﬁndings suggest that transthoracic TDE
s more useful and reliable than ﬂow velocity measurement with
ransthoracic pulsed Doppler echocardiography. The superiority of
DE over pulsed Doppler ﬂowmetry may  be attributed to the differ-
nce in the amplitude of ultrasound reﬂection power between the
yocardium and blood cells because the myocardium is a much
tronger ultrasound reﬂector. However, care must be exercised to
liminate the mitral annular motion signals concomitant with the
DE signal of LAA motion.
AAWV measured by transthoracic TDE in relation to LA
hrombosis and blood stasis
SEC determined by transesophageal echocardiography implies
lood stasis or aggregation and may  be an important risk factor for
erebral embolism [22,23]. Uretsky et al. detected SEC in patients
ith a transthoracic LAAWV ≤13 cm/s with a sensitivity and speci-
city of 97% and 60%, respectively [14]. Tamura et al. showed that
AAWV <8.7 cm/s had a sensitivity of 77% and a speciﬁcity of 76% for
iagnosing LAA thrombus formation and was an independent pre-
ictor of cerebro-vascular events (hazard ratio, 3.460) [13,24].  We
reviously studied the LAAWV during contraction and relaxation
n healthy Japanese subjects and its mean value during contrac-
ion was 22 ± 3 cm/s [20]. We  took 10 cm/s as the LAAWV cutoff
or abnormal low value, because it was a simple index and was
pproximately half the Japanese normal value and its value posi-
ioned between 13 cm/s taken by Uretsky et al. and 8.7 cm/s taken
y Tamura et al. [13,14].  A transthoracic LAAWV <10 cm/s alone
ad a sensitivity and speciﬁcity of 86% and 88%, respectively, for
iagnosing severe SEC in Japanese patients. In the present study,
ransthoracic LAAWV values were signiﬁcantly lower with increas-
ng SEC severity. Thus, a low LAAWV value may  be an important
ndicator of blood stasis or aggregation in the LAA.83 66
g left atrial appendage contraction.
Clinical value of transthoracic LAAWV in relation to CHADS2 score
The CHADS2 score is a widely used clinical index for evaluat-
ing the risk of thromboembolism and deciding whether to initiate
anticoagulant therapy in patients with nonvalvular AF [16]. We also
found that a CHADS2 score ≥3 had a relatively high sensitivity and
speciﬁcity for diagnosing cerebral embolism and/or LAA thrombus.
These results support the use of a high CHADS2 score not only as
a diagnostic aid for evaluating the risk of thrombosis but also as a
clinical indicator for starting anticoagulant therapy in patients with
persistent AF. However, since the CHADS2 score includes stroke
with a value of 2, using it to determine the sensitivity of predicting
prior stroke is tautological. Virtually all clinicians would antico-
agulate a patient with chronic AF who  has already had a stroke.
A CHADS2 score of ≥3 may  be useful for the secondary preven-
tion of stroke, but it may  not be enough for primary prevention of
stroke in AF patients, because, a CHADS2 score may  not be always
consistent with LAA function. Therefore, we tested the clinical sig-
niﬁcance of the transthoracic LAAWV as an additional noninvasive
aid for evaluating LAA function and thrombogenesis. Severe SEC in
the left atrium is a well-known marker of a high risk for thrombosis.
The prediction of SEC severity would be clinically useful because we
currently anticoagulate all patients with severe SEC regardless of
the presence or absence of prior stroke [25–27].  We found that a
LAAWV <10 cm/s had high sensitivity and speciﬁcity for diagnos-
ing severe SEC; in addition, LAAWV was signiﬁcantly lower with
increasing SEC severity. It is important to noninvasively evaluate
SEC for primary prevention of stroke in AF patients with a low
CHADS2 score. In the present study, severe SEC was  noted in 13
of the 46 persistent AF patients with a CHADS2 score ≤1 and in 6
patients with severe SEC even in the 21 patients with a CHADS2
score 0. In the 46 patients with a CHADS2 score ≤1, a transthoracic
LAAWV <10 cm/s had a sensitivity and speciﬁcity of 74% and 91%
for diagnosing severe SEC. In the 21 persistent AF patients with
a CHADS2 score 0, a transthoracic LAAWV <10 cm/s had a sensi-
tivity and speciﬁcity of 44% and 83% for diagnosing severe SEC.
Thus, a transthoracic LAAWV <10 cm/s may  be a speciﬁc diagnos-
tic tool for evaluating severe SEC in the patients judged as having
a low risk for thrombosis according to the CHADS2 score. From
this perspective, a transthoracic LAAWV <10 cm/s may  be a simple
and convenient indicator for starting anticoagulation therapy and
may  prevent primary stroke in the patients judged as low risk for
thromboembolism according to their CHADS2 score. Moreover, we
could spare patients with AF with a CHADS2 score ≤2 and normal
LAAWV from anticoagulation therapy to avoid related complica-
tions, while optimal anticoagulation strategy for stroke prevention
has been now investigated in Japanese patients with AF, J-RHYTHM
Registry study design [28].
LimitationsOne of the major limitations of this study is its retrospective
design as opposed to a randomized prospective one. The number
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It is necessary to correct the angle of the ultrasonic Doppler
eam when measuring transthoracic LAAWV; the Doppler beam
ngle ranged from 10◦ to 50◦ in the present study, which may
ave caused some errors. However, in the present study, the
AAWV values were almost equal between transthoracic and trans-
sophageal measurements. We  previously reported the correction
f the Doppler beam angle by observing the direction of the
ongitudinally contracting appendage in normal subjects [20].
nother limitation of this study might be the ultrasonic view used
o obtain the transthoracic LAAWV; we chose the parasternal short-
xis view for determining LAAWV. Uretsky et al. and Sallach et al.
ound no differences in the assessment of LAA wall motion between
he parasternal and apical views in transthoracic echocardiography
14,15]. In the present study, the sample volume was  placed as close
s possible to the tip of the LAA since it is the most mobile point in
he LAA. However, the regional LAA wall motion may  in fact have
ifferent myocardial motion velocities. Further studies are required
o elucidate the signiﬁcance of regional wall motion in the LAA.
onclusions and implications
Despite some methodological limitations, transthoracic LAAWV
ay  be a useful noninvasive tool for estimating LAA function and
hrombogenesis especially in patients with a low CHADS2 score
ith persistent AF.
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